EP0140109A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Allograft of reduced immunogenicity and method and reagent for making same
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1984-09-14
•
Granted: —
•
Expires: 2004-09-14
Abstract
Abstract Allograft survival is enhanced by pretreating the allograft with an immunotoxin against an Ia equivalent antigen borne by the allograft to deplete the allograft of cells that bear the antigen thereby reducing the ability of the allograft to stimulate an immune response from the recipient of the allograft.
Inventors
- 👤 C. Garrison Fathman
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 13:43
CPC Classifications
C; C07; C07K; C07K17/00; C07K17/02; C07K17/06; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6817; A61K47/6819; A61K47/6825; A61K47/6827
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
29 words
Method of reducing the immunogenicity of an allograft characterized in that the allograft is contacted before transplantation with an immunotoxin to an Ia equivalent antigen borne by the allograft.
Claim 2
Dependent Claim
29 words
Method of reducing the immunogenicity of an allograft characterized in that the allograft is contacted before transplantation with an immunotoxin to an Ia equivalent antigen borne by the allograft.
Claim 3
Dependent Claim
33 words
The method of claim 1 further characterized in that the allograft is contacted with at least about 1 µg of immunotoxin per 1 x 10 6 Ia equivalent antigen-bearing cells of the allograft.
Claim 4
Dependent Claim
24 words
The method of claim 1 further characterized in that the allograft is a human allograft and the Ia equivalent antigen is an HLA-DR antigen.
Claim 5
Dependent Claim
24 words
The method of claim 1 further characterized in that the immunotoxin is a conjugate of an anti-Ia equivalent monoclonal antibody and ricin A chain.
Claim 6
Dependent Claim
21 words
An allograft characterized in that the allograft is pretreated with an immunotoxin to an Ia equivalent antigen borne by the allograft.
Claim 7
Dependent Claim
21 words
An allograft characterized in that the allograft is pretreated with an immunotoxin to an Ia equivalent antigen borne by the allograft.
Claim 8
Dependent Claim
24 words
The allograft of claim 5 further characterized in that the allograft is a human allograft and the Ia equivalent antigen is an HLA-DR antigen.
Claim 9
Dependent Claim
24 words
The allograft of claim 5 further characterized in that the immunotoxin is a conjugate of an anti-Ia equivalent monoclonal antibody and ricin A chain.
Claim 10
Dependent Claim
38 words
An immunotoxin comprising a toxin component conjugated to an antibody characterized in that the immunotoxin is for use in reducing the immunogenicity of an allograft and the antibody is to an Ia equivalent antigen borne by the allograft.
Claim 11
Dependent Claim
38 words
An immunotoxin comprising a toxin component conjugated to an antibody characterized in that the immunotoxin is for use in reducing the immunogenicity of an allograft and the antibody is to an Ia equivalent antigen borne by the allograft.
Claim 12
Dependent Claim
24 words
The immunotoxin of claim 8 further characterized in that the allograft is a human allograft and the Ia equivalent antigen is an HLA-DR antigen.
Claim 13
Dependent Claim
23 words
The immunotoxin of claim 8 further characterized in that the toxin component is ricin A chain and the antibody is a monoclonal antibody.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.